DAWN Q3 EPS Estimate Boosted by Capital One Financial

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Stock analysts at Capital One Financial increased their Q3 2024 EPS estimates for Day One Biopharmaceuticals in a research note issued to investors on Wednesday, October 16th. Capital One Financial analyst N. Quibria now anticipates that the company will post earnings of ($0.71) per share for the quarter, up from their prior estimate of ($0.79). The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($1.68) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals’ Q4 2024 earnings at ($0.73) EPS and FY2024 earnings at ($2.21) EPS.

A number of other research analysts also recently issued reports on DAWN. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. JPMorgan Chase & Co. cut their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, Needham & Company LLC increased their price objective on Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Trading Down 0.5 %

Day One Biopharmaceuticals stock opened at $15.01 on Monday. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $18.07. The company has a market cap of $1.31 billion, a PE ratio of -5.98 and a beta of -1.51. The company’s 50-day moving average is $14.05 and its two-hundred day moving average is $14.37.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.70. The company had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares of the company’s stock, valued at approximately $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares in the company, valued at $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the sale, the insider now owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,748 shares of company stock valued at $689,072 over the last ninety days. 8.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DAWN. Deerfield Management Company L.P. Series C lifted its holdings in Day One Biopharmaceuticals by 65.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after purchasing an additional 1,157,825 shares in the last quarter. Estuary Capital Management LP increased its position in shares of Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock valued at $26,616,000 after purchasing an additional 728,240 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at about $7,387,000. Goldman Sachs Group Inc. increased its stake in Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after purchasing an additional 472,654 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in Day One Biopharmaceuticals in the 2nd quarter worth approximately $6,480,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.